The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 25, 2019

Filed:

Jul. 05, 2017
Applicant:

Glaxosmithkline Biologicals SA, Rixensart, BE;

Inventors:

Maurizio Comanducci, Siena, IT;

Mariagrazia Pizza, Siena, IT;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/00 (2006.01); A61K 39/095 (2006.01); C07K 14/22 (2006.01); A61K 39/102 (2006.01); A61K 39/39 (2006.01); C07K 14/285 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/095 (2013.01); A61K 39/102 (2013.01); A61K 39/39 (2013.01); C07K 14/22 (2013.01); C07K 14/285 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/575 (2013.01); C07K 2319/00 (2013.01);
Abstract

Meningococcal protein NMB 1870 has been described in the prior art. The inventors have found that NMB 1870 is an effective antigen for eliciting anti-meningococcal antibody responses, and that it is expressed across all meningococcal serogroups. Forty-two different NMB 1870 sequences have been identified, and these group into three variants. Serum raised against a given variant is bactericidal within the same variant group, but is not active against strains which express one of the other two variants i.e. there is intra-variant cross-protection, but not inter-variant cross-protection. For maximum cross-strain efficacy, therefore, the invention uses mixture comprising different variants of NMB 1870.


Find Patent Forward Citations

Loading…